UK Beats Europe to Approving Eli Lilly's Obesity Pill

MHRA clears Foundayo for weight loss as a NICE reimbursement decision looms in November.

11 Aug 2026

The UK has become the first country in Europe to authorize Eli Lilly's oral obesity treatment. The Medicines and Healthcare products Regulatory Agency cleared orforglipron, sold as Foundayo, for weight management and type 2 diabetes on 10 August, following what it called a rigorous review of the tablet's safety, quality, and effectiveness.

The authorization covers adults with a body mass index of 30 or above, or between 27 and 30 with at least one weight-related condition, for use alongside a reduced-calorie diet and more physical activity. Unlike some oral GLP-1 rivals, the once-daily tablet can be taken at any time without food or water restrictions, a convenience the company has pitched as a real edge over competing formulations.

Lilly's international president has already signaled a broader European strategy built around direct-to-consumer telehealth rather than reliance on government reimbursement alone, and the approval lands right on schedule for that plan. Speaking to Reuters in June, the executive said the company intends to pair European launches with the same telehealth partnerships it has used in the US, while acknowledging that a pricing deal with the American government will shape how hard it pushes for public coverage elsewhere.

Attention now turns to the National Institute for Health and Care Excellence, which is running its own appraisal of the drug's clinical and cost effectiveness. A decision on National Health Service funding is expected on 18 November, and the outcome will determine how quickly Lilly's telehealth-first approach needs to give way to formal reimbursement talks if it wants real uptake beyond the private market.